Effects of Niceritrol on Serum Lipids and Apolipoproteins in Patients with Hyperlipidemia

The effects of niceritrol on serum lipids and apolipoproteins were investigated in 29 patients with hyperlipidemia for 12 weeks. Total cholesterol was decreased significantly by 5.4% after the treatment without lowering HDL cholesterol. The atherogenic index was decreased significantly. Serum triglyceride had a tendency to decrease but not significantly. In 13 patients with hypertrigly-ceridemia (more than 150mg/dl of triglyceride), serum triglyceride was decreased by 20%. The apolipoproteins A-I, A-II and B were decreased significantly. There were no effects on apolipoprotein C-II and C-III. Apolipoprotein E decreased significantly. Flushing occurred in 5 patients with hyperlipidemia, but other major side effects did not occure. These results suggested that niceritrol was effective in treatment of patients with hyperlipidemia.